| Literature DB >> 27905309 |
M J van der Steen1, Y R P de Waal, A Westermann, B Tops, W Leenders, P B Ottevanger.
Abstract
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27905309
Source DB: PubMed Journal: Neth J Med ISSN： 0300-2977 Impact factor: 1.422